triple negative breast cancer

[Telix Pharmaceuticals] Telix Pharmaceuticals Limited announced that a first patient has been dosed in a Phase II study of TLX250-CDx in patients with TNBC.

[Molecular Therapy-Oncolytics] Researchers developed a plasmid-vector encoding for the secreted fusion protein sCV1-hIgG1, comprising of highly efficient CD47-blocking moiety CV1 and Fc domain of human IgG1 with maximized immune activation.

[npj Breast Cancer] To find metastatic recurrence biomarkers of TNBC treated by neoadjuvant chemotherapy and anti-EGFR antibodies, investigators evaluated tumor genomic, transcriptomic, and immune features, using MSK-IMPACT assay, gene arrays, Nanostring technology, and TIL assessment on H&E.

[Proceedings of the National Academy of Sciences of the United States of America] Using a murine TNBC model, scientists showed that USP9x knockdown abrogated Notch activation, reducing the production of the proinflammatory cytokines, C-C motif chemokine ligand 2 and interleukin-1 beta.

[T–Cure Bioscience, Inc.] T–Cure Bioscience, Inc. announced that the US FDA has approved the Investigational New Drug application to initiate a Phase I clinical study evaluating a T cell receptor (TCR)–based product candidate for the treatment of tumors expressing Kita–Kyushu lung cancer antigen 1 (KK-LC-1), such as gastric, cervical, lung, breast cancers and other KK–LC–1 positive epithelial cancers.

[Cell Chemical Biology] The PIM family of kinases has emerged as a factor that is both overexpressed in TNBC and associated with poor outcomes. The authors' screening effort identified PIM and the 20S proteasome inhibition as the most synergistic combination.